



COPY OF PAPERS
ORIGINALLY FILED

6/c

UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 2 8 2002

TECH CENTER 1600/2900

Applicants: Philip John Burke and Richard John Knox

Serial No.: 10/099,830

Filed: March 13, 2002

For: "THERAPEUTIC SYSTEMS"

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination, please amend the application as follows. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 50-1868.

In the Claims

C¹ 29. (Twice Amended) A method of treating a human patient with a target cell to be destroyed wherein the target cell expresses NQO2 the method comprising administering to the patient a prodrug which is converted to a cytotoxic drug by the action of NQO2 and nicotinamide riboside (reduced) (NRH) or an analogue thereof which can pass reducing equivalents to NQO2, wherein the prodrug is CB 1954 and analogs thereof.

Please cancel claim 30.

C² 41. (New) The method of claim 29, wherein the analogue of NRH is 1-(carboxamidomethyl)-di-hydronicotinamide.

524202v1

ERD 100 CON
078230/00031